[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interaction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interaction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100569337","early-phase-1-effects-of-a-hemp-product-on-the-pharmacokinetics-and-pharmacodynamics-of-clopidogrel-100569337",false,"NCT06692933","Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel","Inclusion Criteria:\n\n* 21-64 years old and healthy;\n* Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;\n* Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements\u002Fbotanical products known to alter the pharmacokinetics of cannabis and\u002For clopidogrel;\n* Have taken hemp or cannabis (in any form) before and tolerated it well;\n* Willing to abstain from consuming dietary supplements\u002Fbotanical products and citrus juices for the duration of the study;\n* Willing to abstain from cannabis\u002Fmarijuana, hemp, THC- and\u002For CBD-containing products for several weeks;\n* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day;\n* Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day;\n* Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study;\n* Have the ability to and are willing to comply with the requirements of the study;\n* Geographically located within a 40-mile radius of Spokane and have the time to participate and;\n* Can read and speak English\n\nExclusion Criteria:\n\n* Under the age of 21 or over the age of 64;\n* Any major illness;\n* Pregnant or nursing;\n* History of allergy or intolerance to cannabis or clopidogrel;\n* Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements\u002Fbotanical products known to alter the pharmacokinetics of cannabis and\u002For clopidogrel;\n* Never taken cannabis (in any form) before;\n* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data;\n* Currently using or have recently used drugs or other illicit substances for recreational purposes;\n* Have used cannabis\u002Fmarijuana, hemp, THC- and\u002For CBD-containing products within the last 4 weeks;\n* Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or;\n* Unable to read and speak English",true,"ALL","21 Years","64 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.",[27],"Interaction",[29,30,31,32,33,34],"CYP2C19","pharmacokinetics","hemp","CBD","natural product","clopidogrel","RECRUITING","2026-06-02",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":39},"2024-06-20",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Washington State University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":15,"sex":16,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100569416","early-phase-1-evaluating-the-pharmacokinetics-of-oregano-and-potential-oregano-drug-interactions-using-a-drug-cocktail-approach-100569416","NCT06693960","Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach","Inclusion Criteria:\n\n* Between 18-64 years old and healthy\n* Not taking any medications (prescription and non-prescription) or dietary\u002Fherbal supplements that can interfere with study drug pharmacokinetics\n* Willing to abstain from consuming dietary\u002Fherbal supplements and citrus juices for several weeks\n* Willing to abstain from cannabis\u002Fmarijuana, hemp, and THC- and CBD-containing products for several weeks\n* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and the morning of the first day of each study arm\n* Willing to abstain from consuming any alcoholic beverages for at least 1 day prior to any study day and during the study day\n* Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms). Specifically, regardless of the use hormonal-based birth control, a non-hormonal method should be used for the duration of the study and for three weeks following cessation of participation.\n* Willing to abstain from consuming oregano (as a food additive or otherwise) for the duration of the study\n* Geographically located within a 40-mile radius of Spokane and have the time to participate\n\nExclusion Criteria:\n\n* Under 18 or over 64 years old\n* Taking medications or dietary\u002Fherbal supplements that can interfere with study drug pharmacokinetics\n* Have a major illness\n* Taking medication\u002Fsupplements for a mineral deficiency\n* History of intolerance or allergy to oregano or any of the cocktail drugs (caffeine, dextromethorphan, losartan, midazolam, and omeprazole)\n* Use of cannabis\u002Fmarijuana, hemp, and CBD- and\u002For THC-containing products within the last month\n* Currently using drugs or illicit substances for recreational purposes\n* Pregnant or nursing\n* Geographically located outside the 40-mile radius of Spokane and do not have the time to participate\n* Cannot read and speak English","18 Years",{"count":56,"type":21},16,[24],"The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.",[27],[30,61,62,63,64,65],"drug interaction","natural products","oregano","cytochrome P450","cocktail",{"date":38,"type":39},{"date":68,"type":39},"2024-09-26",{"date":70,"type":21},"2027-01-31",{"name":45,"class":46},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":15,"sex":16,"minAge":54,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":47},"100520195","early-phase-1-contribution-of-ugt2b17-to-the-pharmacokinetics-of-diclofenac-100520195","NCT06053411","Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac","Pilot Study to Assess the Contribution of UGT2B17 and Associated Genetic Polymorphisms on the Pharmacokinetics of Diclofenac Alone and Upon Co-administration With Curcumin","Inclusion Criteria:\n\n* Aged from 18-64 years and healthy\n* Not taking any medications (prescription and non-prescription) or dietary\u002Fherbal supplements known to alter the pharmacokinetics of diclofenac or curcumin\n* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of the first day of each study arm\n* Willing to abstain from consuming any alcoholic beverages for one day prior to any study day, during the 14-hour inpatient days, and for the outpatient visit(s) following the 14-hour days\n* Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms)\n* Have the time to participate\n* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for the subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Under the age of 18 or over the age of 65 years\n* Smoke\u002Fvape\u002Fchew tobacco products\n* Use cannabis products, including marijuana, hemp, and other THC- or CBD-containing products\n* Have any current major illness or chronic illness such as (but not limited to) kidney disease, hepatic disease, diabetes mellitus, hypertension, coronary artery disease, chronic obstructive pulmonary disease, cancer, or HIV\u002FAIDS\n* History of anemia or any other significant hematologic disorder\n* History of drug or alcohol addiction or major psychiatric illness\n* Pregnant or nursing or plan to become pregnant within 3 weeks after participation\n* History of allergy intolerance to diclofenac or curcumin\n* Taking concomitant medications, both prescription and non-prescription (including dietary supplements\u002Fherbal products), known to alter the pharmacokinetics of diclofenac or curcumin\n* Taking any turmeric spice or curcumin supplement\n* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or quality of the data\n* Out-of-range clinical laboratory value that the study physician considers participation in the study a health risk","65 Years",{"count":81,"type":21},30,[24],"The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.",[27],[86],"Pharmacokinetic",{"date":38,"type":39},{"date":89,"type":39},"2024-03-01",{"date":91,"type":21},"2026-12-18",{"name":45,"class":46}]